Free Articles
Free to read — no membership required.
I Have APOE4. What Do I Do Now?
Written for someone who has just received an APOE4 result and does not yet know what it means — what the genotype does, what it does not, and the actions that have evidence behind them.
What APOE4 Means: A Practical Guide for Patients
What carrying one or two copies of APOE ε4 means for your brain, your risk, and the decisions in front of you — in plain language.
APOE 2, 3, and 4: What the Three Versions of This Gene Actually Do
Three versions of one gene, separated by two amino acids — and why that small difference sends Alzheimer’s risk in three different directions.
APOE ε4 Risk Is Not the Same in Every Population
The widely quoted risk figures come almost entirely from people of European ancestry. How much the numbers change elsewhere, and the haplotype explanation for why.
DHA and Brain Health: A Guide for APOE ε4 Carriers
Timing and molecular form both matter. What the DHA trials show for carriers before symptoms begin, and what they show after.
APOE ε4 or ApoE4? A Clinician’s Guide to Correct Nomenclature
Gene, allele, protein isoform, and search term are four different things. A short reference for using each correctly in writing and in clinic.
Stem Cells, Exosomes, and Peptides for Alzheimer’s Disease: What the Evidence Shows
A clinical review of regenerative therapies marketed to APOE ε4 carriers — what randomized evidence actually supports, and where it doesn’t.
The End of Alzheimer’s Program: A Neurologist’s Review
A board-certified neurologist and APOE ε4 carrier reviews Dale Bredesen’s bestselling protocol — what the evidence supports, and where it overclaims.
No More Sleepless Nights: A Neurologist’s Review
A physician’s review of a popular sleep program, and what the evidence actually says about sleep and APOE ε4 risk.
Why Some Scientists Question the Amyloid Hypothesis
Why the leading theory of Alzheimer’s disease is being challenged — and why it doesn’t change what APOE ε4 carriers should do.
Alzheimer’s Treatments and Emerging Therapies: A Guide for APOE ε4 Carriers
Current FDA-approved therapies, what’s in clinical trials, and what APOE ε4 status means for treatment candidacy.
Navigating Pre-Death Grief: Managing the Emotional Toll of Dementia Caregiving
The grief that begins long before the death does — why it is so often unrecognized, and what helps caregivers carry it.
Key Considerations After a Dementia Diagnosis in APOE ε4 Carriers
The decisions that matter most in the first months after a diagnosis, and the ones that can safely wait.
Who Helps After a Dementia Diagnosis? Building Your Care Team
Who belongs on the care team after a dementia diagnosis — and how to actually find a geriatric psychiatrist or social worker.
Intermittent Fasting: A Patient Guide
What intermittent fasting has been shown to do for brain aging, what remains mechanistic only, and who should not attempt it.
APOE ε4 Carriers and Meat
Dietary meat intake and cognitive outcomes in APOE ε4 carriers, and what the observational data can and cannot establish.
Member-Only Articles
Full clinical reviews and evidence tables. Become a member to unlock the complete library.
-
The Most Nutritious Foods for Brain Health
A practical breakfast, lunch, and dinner guide using nutrient-dense proteins, healthy fats, and high-fiber carbohydrates.
-
A Daily Guide to Better Brain Health for MCI and Early Dementia
A clear, step-by-step daily plan to support brain health and make life easier for people with mild cognitive…
-
Farmed Fish and Shrimp: The Public Health Trade-Offs of Modern Aquaculture
Aquaculture carries the highest antimicrobial use intensity of any food-animal sector (164.8 mg/kg). What the evidence shows about…
-
Do Leqembi and Kisunla Meaningfully Help?
Lecanemab slowed decline by 0.45 CDR-SB points (27%) in CLARITY AD; donanemab by 22–36% in TRAILBLAZER-ALZ 2. Does…
-
Creatine and Cognition in APOE ε4 Carriers: What the Evidence Actually Shows
No randomized trial has tested creatine in mild cognitive impairment, and the only Alzheimer study is a 20-person…
-
Lecanemab vs Donanemab: Why the Amyloid Target Matters
Lecanemab binds soluble protofibrils and is dosed continuously; donanemab binds pyroglutamate plaque amyloid and can be stopped after…
-
Why Do Some APOE4 Carriers Never Develop Dementia?
Some APOE ε4 carriers reach old age with Alzheimer’s pathology in the brain and their thinking intact. What…
-
I Have Two Copies of APOE4. Am I Going to Get Alzheimer’s?
Two copies of APOE ε4 makes Alzheimer’s biology in the brain close to universal with age. It does…
-
Clinical Trial Evaluation Guide: Assessing Candidacy and Risk as an APOE ε4 Carrier
In CLARITY AD, lecanemab slowed decline on CDR-Sum of Boxes by 0.45 points over 18 months (95% CI…
